Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Release Testing For Gene Therapy Market Size, Value And Growth Trends Through 2030
The release testing for gene therapy market size has experienced rapid expansion in recent years. This market is projected to expand from $1.43 billion in 2025 to $1.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.3%. Historically, this growth has stemmed from an increase in gene therapy trials, stringent regulatory quality standards, heightened viral vector production, the proliferation of biologics testing labs, and a rise in advanced therapy approvals.
Significant expansion is anticipated for the release testing for gene therapy market size over the next few years. The market is poised to reach $3.08 billion by 2030, with a compound annual growth rate (CAGR) of 16.5%. Factors contributing to this growth during the forecast period include the proliferation of commercial gene therapies, an escalating requirement for rapid release testing, the widening scope of contract testing services, heightened regulatory scrutiny, and the integration of automated quality control platforms. Prominent trends expected in the forecast period are high-sensitivity potency assays, rapid sterility testing platforms, automated batch release analytics, multi-parameter quality control panels, and advanced vector identity testing.
Download A Free Sample Report For Comprehensive Market Insights:
Release Testing For Gene Therapy Market Growth Drivers: What Factors Are Accelerating Expansion?
The market for release testing for gene therapy is anticipated to grow due to the rising number of global gene therapy approvals. Gene therapies are defined as medical interventions involving the manipulation (introduction, removal, or alteration) of genetic material within a patient’s cells to manage or avert illnesses. The increase in worldwide approvals for gene therapies stems from greater regulatory acceptance, scientific progress, and a growing need for novel solutions for genetic conditions that were previously uncurable. Release testing for gene therapy is a mandatory regulatory step, ensuring product quality and patient safety via evaluations of potency, purity, identity, and overall safety before a batch is released. For example, data from the National Center for Biotechnology Information, a U.S. governmental research source, indicated in November 2023 that over 100 gene, cell, and ribonucleic acid (RNA) therapies had received global approval by early 2023, with more than 3,700 others undergoing clinical and preclinical development. Consequently, the expanding volume of global gene therapy approvals is projected to boost the growth of the release testing for gene therapy market.
Release Testing For Gene Therapy Market Segment Analysis: What Are The Major Market Categories?
The release testing for gene therapy market covered in this report is segmented –
1) By Test Type: Potency Testing; Purity Testing; Identity Testing; Safety Testing; Sterility Testing; Other Test Types
2) By Product Type: Assay Kits; Reagents; Instruments; Services
3) By Therapy Type: In Vivo Gene Therapy; Ex Vivo Gene Therapy
4) By Application: Clinical Diagnostics; Research; Quality Control; Process Development; Other Applications
5) By End-User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Contract Research Organizations; Other End-Users
Subsegments:
1) By Potency Testing: Functional Activity Assays; Gene Expression Level Measurement; Biological Activity Evaluation; Dose Response Assessment
2) By Purity Testing: Residual Host Cell Protein Analysis; Residual Deoxyribonucleic Acid Quantification; Process Related Impurity Testing; Product Related Impurity Assessment
3) By Identity Testing: Genetic Sequence Confirmation; Vector Identity Verification; Transgene Identity Analysis; Cell Line Authentication
4) By Safety Testing: Adventitious Agent Testing; Replication Competent Virus Detection; Endotoxin Level Evaluation; Toxicity Assessment
5) By Sterility Testing: Bacterial Contamination Testing; Fungal Contamination Testing; Mycoplasma Detection; Environmental Monitoring Validation
6) By Other Test Types: Stability Testing; Packaging Integrity Testing; Shelf Life Determination; Transport and Storage Condition Testing
Release Testing For Gene Therapy Market Trends: What Is Shaping Future Industry Growth?
Leading firms within the release testing for gene therapy market are concentrating on creating cutting-edge solutions, like digital PCR-based analytical testing platforms, to address the increasing demand for highly precise, sensitive, and standardized methods crucial for guaranteeing the safety, effectiveness, and regulatory adherence of intricate gene therapy products. Digital polymerase chain reaction (PCR)-based analytical testing platforms represent sophisticated molecular systems capable of accurately quantifying deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) by dividing samples into thousands of distinct reactions, thereby facilitating extremely sensitive and absolute measurement of nucleic acid targets. As an example, in April 2025, QIAGEN N.V., a Germany-based company supplying molecular diagnostics and life science instruments, augmented its QIAcuity digital PCR portfolio with novel lentivirus solutions specifically engineered to improve quality control within cell and gene therapy manufacturing processes. These new solutions facilitate viral vector genome titration, vector copy number determination, and the detection of replication-competent lentiviruses, allowing for highly precise analytics in process development, batch release, and maintaining regulatory compliance. The platform delivers absolute quantification across both singleplex and multiplex applications, exhibits robust repeatability, and includes customized kits for essential gene therapy vectors, ensuring outcomes that are more dependable and consistent compared to numerous traditional testing methodologies.
Release Testing For Gene Therapy Market Leading Companies Driving Competitive Growth
Major companies operating in the release testing for gene therapy market are Thermo Fisher Scientific Inc., Boehringer Ingelheim BioXcellence GmbH, Fujifilm Diosynth Biotechnologies Inc., AGC Biologics Inc., SGS SA, Lonza Group AG, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., Sartorius AG, Samsung Biologics Co. Ltd., Bio-Rad Laboratories Inc., Pace Analytical Services LLC, KBI Biopharma Inc., BioAgilytix Labs LLC, Viralgen Vector S.L., GenScript ProBio LLC, KCAS Bioanalytical Services, Creative Biolabs LLC, Cellipont Bioservices Inc.
Access The Complete Release Testing For Gene Therapy Market Report:
Release Testing For Gene Therapy Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the release testing for gene therapy in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the release testing for gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.